Press Releases AstraZeneca PLC Xetra

Equities

ZEG

GB0009895292

Market Closed - Xetra Other stock markets 11:35:31 2024-06-07 am EDT			After market 12:18:52 pm
148.2 ^EUR	0.00%		148.8	+0.37%

10:16am	ASTRAZENECA : JP Morgan reiterates its Buy rating	ZD
Jun. 05	Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During Bio International Convention 2024 to Establish New Rare Diseases Centre of Excellence	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	08:43am	AQ
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'	Jun. 06	AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal	Jun. 06	AQ
AstraZeneca - Acquisition of Fusion completed	Jun. 05	AQ
AstraZeneca : Biographies	Jun. 03	PU
AstraZeneca : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	Jun. 03	PU
AstraZeneca : Transparency Directive - Form 6-K	Jun. 03	PU
AstraZeneca immunotherapy could boost lung cancer survival	Jun. 03	AQ
AstraZeneca : Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K	Jun. 03	PU
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	Jun. 02	BU
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	Jun. 02	PU
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	Jun. 02	BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy	Jun. 02	BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	May. 28	AQ
Expansion of AstraZeneca's flagship health equity programme Healthy Heart Africa	May. 28	AQ
Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension	May. 28	AQ
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	May. 27	BU
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	May. 23	BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	May. 22	BU
Astrazeneca looks to double revenue in 'new era of growth'	May. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT